Fox Business - The Power to Prosper
Search Site

Amylin Pharmaceuticals

Novo Nordisk Upgraded to 'Buy'

Novo Nordisk (NYSE:NVO) was handed an upgrade to "buy" from "hold" on Tuesday from Austria's Erste Group, helping to boost its shares 1%.The Denmark-based drug giant, which competes with Bristol-Myers Squibb (NYSE:BMY), Sanofi (NYSE:SNY) and Amylin Pharmaceuticals (NASDSAQ:AMLN), also confirmed a share buyback program launched on Jan. 30.Under the plans, it expects to buy back up to 15 billion Danish Krone ($2.8 billion) worth of its shares over the next 12 months.Shares of Novo Nordisk were up 0.90% to $44.29 in recent trade. They have risen 37% over the last year....

Read More

  1. Bristol-Myers Posts 3rd-Quarter Loss on Hepatitis C Drug Loss, Sales Down 30%

    Bristol-Myers Squibb Co. (BMY) swung to a third-quarter loss on the costly failure of an experimental hepatitis C drug, while a steeper-than-expected drop in sales o...

  2. Bristol-Myers Sales Slump 30% on Generic Pressure

    Bristol-Myers Squibb (NYSE:BMY) reported a sharp decline in third-quarter sales and a weaker-than-expected adjusted profit on Wednesday as it continued to grapple wi...

  3. Eli Lilly Sales Slide 11% on 'Patent Cliff' Struggles

    Hurt by rising generic competition for its schizophrenia drug Zyprexa, Eli Lilly (NYSE:LLY) reported a sharp decline in sales and adjusted earnings on Wednesday, tho...

  4. Eli Lilly Net Up 7.3% on Gain

    Drug maker Eli Lilly & Co. (LLY) reported a 7% increase in third-quarter profit, as a one-time payment from a former partner helped offset an 11% sales decline drive...

  5. Eli Lilly 3rd-Quarter Net Up 7% on Gain;Gross Margins Decline

    Drug maker Eli Lilly & Co. (LLY) reported a 7% increase in third-quarter profit, as a one-time payment from a former partner helped offset an 11% sales decline drive...

  6. Eli Lilly 3rd-Quarter Net Up 7.3% on Gain; Revenue, Margins Decline

    Eli Lilly & Co.'s (LLY) third-quarter earnings rose 7.3% on a gain tied to a payment from a former partner as margins shrank amid lower-than-expected revenue.Results...

  7. EARNINGS PREVIEW: U.S. Drug Makers Struggle With Loss of Exclusivity in 3rd Quarter

    TAKING THE PULSE: Most major U.S. drug makers in the third quarter continued with efforts to cope with the recent losses of market exclusivity for former blockbuster...

  8. Icahn Reports Higher Stake in Take-Two, Lower Stake in Commercial Metals

    Carl Icahn reported in a regulatory filing late Tuesday a higher stake in video-game maker Take-Two Interactive Software Inc. (TTWO) and reduced holdings in steel ma...

  9. Eli Lilly To Record $1.26 Billion Benefit from Amylin

    Eli Lilly & Co. (LLY) revised its full-year guidance to reflect a $1.26 billion payment by Amylin Pharmaceuticals Inc. (AMLN), following the completion of Amylin's a...

  10. Eli Lilly Boosts 2012 Net Profit Forecast

    Eli Lilly and Co on Thursday raised its net profit forecast for 2012 to reflect income from the early payment of financial obligations from former partner Amylin Pha...

  11. AstraZeneca: Bristol-Myers Squibb Completes Purchase of Amylin

    AstraZeneca PLC (AZN.LN) and Bristol-Myers Squibb said Thursday that following the successful completion of the acquisition of Amylin Pharmaceuticals by Bristol-Myer...

  12. Bristol-Myers Exec Arrested for Insider Trading

    Shares of Bristol-Myers Squibb (NYSE:BMY) fell more than 7% Thursday after the drug maker halted a hepatitis C trial and U.S. officials arrested executive Robert Ram...

  1. AstraZeneca to Buy Bristol's Stake in Venture

    AstraZeneca (NYSE:AZN) agreed on Thursday to buy Bristol-Myers Squibb's (NYSE:BMY) stake in their diabetes joint venture for up to $4.1 billion.The London-based biop...

  2. Ex-Bristol-Myers executive gets one-year prison for insider trading

    A former Bristol-Myers Squibb Co finance executive who pleaded guilty to insider trading was sentenced on Wednesday to one year and one day in prison, federal prosec...

  3. Former Bristol-Myers executive admits to insider trading

    A former Bristol-Myers Squibb Co finance executive on Monday pleaded guilty to an insider trading charge, admitting to buying stock options in a biotechnology compan...

  4. Bristol-Myers Profit Drops 45% on Lower Heart Drug Sales

    Bristol-Myers Squibb Co. (BMY) reported a nearly 45% decline in first-quarter profit, as the loss of patent protection for formerly big-selling heart drugs continued...

  5. Bristol-Myers Net Drops on Lower Sales of Heart Drugs

    Bristol-Myers Squibb Co. (BMY) reported a nearly 45% decline in first-quarter profit, as the loss of patent protection for formerly big-selling heart drugs continued...

  6. Eli Lilly Forecasts Stronger 2013

    Eli Lilly (NYSE:LLY) reaffirmed its in-line fiscal 2012 guidance on Friday and unveiled an upbeat outlook for the following year.The company also said it continues t...

  7. S&P Likes a Trio of Biotech ETFs

    Due to increased FDA approvals and takeover speculation, biotechnology ETFs have already been among the best-performing sector funds this year, but more upside could...

‹ Prev1234Next ›
Freebase CC-BY
Source: Amylin Pharmaceuticals on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL